GLP-1 Receptor Agonists: 2026 Landscape Review (UK)

From liraglutide to retatrutide in fifteen years

The GLP-1 receptor agonist class has evolved through three identifiable generations. First-generation daily agonists (exenatide, liraglutide) delivered modest weight reductions of 5-8% over 56-week trial periods and required daily injection. Second-generation weekly agonists, dominated by semaglutide, used C-18 fatty-diacid albumin-binding chemistry to extend the half-life to approximately a week and produced 14-17% mean weight reduction at the 2.4 mg weight-management dose.

The third generation arrived with tirzepatide, a dual GIP/GLP-1 agonist that produced 21-22% mean weight reduction in SURMOUNT-1, and is now being superseded by the triple-agonist retatrutide, which added glucagon-receptor agonism and produced ≈24% mean weight reduction in a shorter (48-week) Phase 2 trial.

The mechanism question

Why has receptor multi-agonism delivered more than additive metabolic effects? Three hypotheses dominate the current literature: (i) GIP-receptor signalling sensitises adipocytes to insulin while modulating macrophage activity, producing improvements in adipose tissue inflammation that pure GLP-1 agonism does not achieve; (ii) glucagon-receptor co-agonism increases resting energy expenditure (animal data suggest 5-10% increases) while accelerating hepatic fatty-acid oxidation; (iii) the simultaneous activation of multiple incretin pathways recreates a physiologically natural post-prandial signal that single-receptor agonists cannot.

Cardiovascular and beyond-weight effects

The SELECT trial (2023) demonstrated that semaglutide 2.4 mg reduced MACE by 20% in adults with overweight or obesity and established cardiovascular disease — the first evidence that GLP-1 agonist weight-loss translates into cardiovascular outcome reduction in a non-diabetic population. SUSTAIN-6 had previously shown MACE benefit in type 2 diabetes. Equivalent CV outcome trials are ongoing for tirzepatide (SURPASS-CVOT, SURMOUNT-MMO) and will be the next major data wave.

UK research context for 2026

For UK researchers, the practical landscape is now: tirzepatide and semaglutide are MHRA-licensed prescription medicines with deep clinical evidence; liraglutide remains a relevant comparator for studies isolating dosing-frequency effects; and retatrutide is the leading candidate to watch through 2025-2027 as Phase 3 TRIUMPH readouts emerge. Compounded or research-grade material remains for laboratory use only across the class.